Docality.com Logo
 
Dr. Nupoor  Gajjar  Md image

Dr. Nupoor Gajjar Md

350 Hawthorne Ave
Oakland CA 94609
510 696-6567
Medical School: Other - 1999
Accepts Medicare: Yes
Participates In eRX: No
Participates In PQRS: Yes
Participates In EHR: No
License #: A76807
NPI: 1023070265
Taxonomy Codes:
207ZC0500X 207ZP0102X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Nupoor Gajjar is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:88307 Description:Tissue exam by pathologist Average Price:$260.00 Average Price Allowed
By Medicare:
$87.41
HCPCS Code:88173 Description:Cytopath eval fna report Average Price:$225.00 Average Price Allowed
By Medicare:
$74.66
HCPCS Code:88331 Description:Path consult intraop 1 bloc Average Price:$200.00 Average Price Allowed
By Medicare:
$65.65
HCPCS Code:88112 Description:Cytopath cell enhance tech Average Price:$185.00 Average Price Allowed
By Medicare:
$61.55
HCPCS Code:88112 Description:Cytopath cell enhance tech Average Price:$185.00 Average Price Allowed
By Medicare:
$61.55
HCPCS Code:88172 Description:Cytp dx eval fna 1st ea site Average Price:$150.00 Average Price Allowed
By Medicare:
$37.40
HCPCS Code:88305 Description:Tissue exam by pathologist Average Price:$139.11 Average Price Allowed
By Medicare:
$39.99
HCPCS Code:88305 Description:Tissue exam by pathologist Average Price:$136.96 Average Price Allowed
By Medicare:
$39.99
HCPCS Code:88342 Description:Immunohistochemistry Average Price:$135.00 Average Price Allowed
By Medicare:
$44.80
HCPCS Code:88342 Description:Immunohistochemistry Average Price:$135.00 Average Price Allowed
By Medicare:
$44.80
HCPCS Code:88304 Description:Tissue exam by pathologist Average Price:$85.00 Average Price Allowed
By Medicare:
$11.94
HCPCS Code:88312 Description:Special stains group 1 Average Price:$90.00 Average Price Allowed
By Medicare:
$28.59
HCPCS Code:88312 Description:Special stains group 1 Average Price:$90.00 Average Price Allowed
By Medicare:
$28.59
HCPCS Code:88300 Description:Surgical path gross Average Price:$35.00 Average Price Allowed
By Medicare:
$4.76
HCPCS Code:88313 Description:Special stains group 2 Average Price:$40.00 Average Price Allowed
By Medicare:
$12.66
HCPCS Code:88313 Description:Special stains group 2 Average Price:$40.00 Average Price Allowed
By Medicare:
$12.66
HCPCS Code:88311 Description:Decalcify tissue Average Price:$40.00 Average Price Allowed
By Medicare:
$13.09

HCPCS Code Definitions

88342
Immunohistochemistry or immunocytochemistry, each separately identifiable antibody per block, cytologic preparation, or hematologic smear; first separately identifiable antibody per slide
88342
Immunohistochemistry or immunocytochemistry, each separately identifiable antibody per block, cytologic preparation, or hematologic smear; first separately identifiable antibody per slide
88112
Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal
88112
Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal
88172
Cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site
88173
Cytopathology, evaluation of fine needle aspirate; interpretation and report
88300
Level I - Surgical pathology, gross examination only
88304
Level III - Surgical pathology, gross and microscopic examination Abortion, induced Abscess Aneurysm - arterial/ventricular Anus, tag Appendix, other than incidental Artery, atheromatous plaque Bartholin's gland cyst Bone fragment(s), other than pathologic fracture Bursa/synovial cyst Carpal tunnel tissue Cartilage, shavings Cholesteatoma Colon, colostomy stoma Conjunctiva - biopsy/pterygium Cornea Diverticulum - esophagus/small intestine Dupuytren's contracture tissue Femoral head, other than fracture Fissure/fistula Foreskin, other than newborn Gallbladder Ganglion cyst Hematoma Hemorrhoids Hydatid of Morgagni Intervertebral disc Joint, loose body Meniscus Mucocele, salivary Neuroma - Morton's/traumatic Pilonidal cyst/sinus Polyps, inflammatory - nasal/sinusoidal Skin - cyst/tag/debridement Soft tissue, debridement Soft tissue, lipoma Spermatocele Tendon/tendon sheath Testicular appendage Thrombus or embolus Tonsil and/or adenoids Varicocele Vas deferens, other than sterilization Vein, varicosity
88305
Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgical margins Breast, reduction mammoplasty Bronchus, biopsy Cell block, any source Cervix, biopsy Colon, biopsy Duodenum, biopsy Endocervix, curettings/biopsy Endometrium, curettings/biopsy Esophagus, biopsy Extremity, amputation, traumatic Fallopian tube, biopsy Fallopian tube, ectopic pregnancy Femoral head, fracture Fingers/toes, amputation, non-traumatic Gingiva/oral mucosa, biopsy Heart valve Joint, resection Kidney, biopsy Larynx, biopsy Leiomyoma(s), uterine myomectomy - without uterus Lip, biopsy/wedge resection Lung, transbronchial biopsy Lymph node, biopsy Muscle, biopsy Nasal mucosa, biopsy Nasopharynx/oropharynx, biopsy Nerve, biopsy Odontogenic/dental cyst Omentum, biopsy Ovary with or without tube, non-neoplastic Ovary, biopsy/wedge resection Parathyroid gland Peritoneum, biopsy Pituitary tumor Placenta, other than third trimester Pleura/pericardium - biopsy/tissue Polyp, cervical/endometrial Polyp, colorectal Polyp, stomach/small intestine Prostate, needle biopsy Prostate, TUR Salivary gland, biopsy Sinus, paranasal biopsy Skin, other than cyst/tag/debridement/plastic repair Small intestine, biopsy Soft tissue, other than tumor/mass/lipoma/debridement Spleen Stomach, biopsy Synovium Testis, other than tumor/biopsy/castration Thyroglossal duct/brachial cleft cyst Tongue, biopsy Tonsil, biopsy Trachea, biopsy Ureter, biopsy Urethra, biopsy Urinary bladder, biopsy Uterus, with or without tubes and ovaries, for prolapse Vagina, biopsy Vulva/labia, biopsy
88305
Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgical margins Breast, reduction mammoplasty Bronchus, biopsy Cell block, any source Cervix, biopsy Colon, biopsy Duodenum, biopsy Endocervix, curettings/biopsy Endometrium, curettings/biopsy Esophagus, biopsy Extremity, amputation, traumatic Fallopian tube, biopsy Fallopian tube, ectopic pregnancy Femoral head, fracture Fingers/toes, amputation, non-traumatic Gingiva/oral mucosa, biopsy Heart valve Joint, resection Kidney, biopsy Larynx, biopsy Leiomyoma(s), uterine myomectomy - without uterus Lip, biopsy/wedge resection Lung, transbronchial biopsy Lymph node, biopsy Muscle, biopsy Nasal mucosa, biopsy Nasopharynx/oropharynx, biopsy Nerve, biopsy Odontogenic/dental cyst Omentum, biopsy Ovary with or without tube, non-neoplastic Ovary, biopsy/wedge resection Parathyroid gland Peritoneum, biopsy Pituitary tumor Placenta, other than third trimester Pleura/pericardium - biopsy/tissue Polyp, cervical/endometrial Polyp, colorectal Polyp, stomach/small intestine Prostate, needle biopsy Prostate, TUR Salivary gland, biopsy Sinus, paranasal biopsy Skin, other than cyst/tag/debridement/plastic repair Small intestine, biopsy Soft tissue, other than tumor/mass/lipoma/debridement Spleen Stomach, biopsy Synovium Testis, other than tumor/biopsy/castration Thyroglossal duct/brachial cleft cyst Tongue, biopsy Tonsil, biopsy Trachea, biopsy Ureter, biopsy Urethra, biopsy Urinary bladder, biopsy Uterus, with or without tubes and ovaries, for prolapse Vagina, biopsy Vulva/labia, biopsy
88307
Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of surgical margins Breast, mastectomy - partial/simple Cervix, conization Colon, segmental resection, other than for tumor Extremity, amputation, non-traumatic Eye, enucleation Kidney, partial/total nephrectomy Larynx, partial/total resection Liver, biopsy - needle/wedge Liver, partial resection Lung, wedge biopsy Lymph nodes, regional resection Mediastinum, mass Myocardium, biopsy Odontogenic tumor Ovary with or without tube, neoplastic Pancreas, biopsy Placenta, third trimester Prostate, except radical resection Salivary gland Sentinel lymph node Small intestine, resection, other than for tumor Soft tissue mass (except lipoma) - biopsy/simple excision Stomach - subtotal/total resection, other than for tumor Testis, biopsy Thymus, tumor Thyroid, total/lobe Ureter, resection Urinary bladder, TUR Uterus, with or without tubes and ovaries, other than neoplastic/prolapse
88312
Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver)
88311
Decalcification procedure (List separately in addition to code for surgical pathology examination)
88312
Special stain including interpretation and report; Group I for microorganisms (eg, acid fast, methenamine silver)
88313
Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry
88313
Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry
88331
Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1467422550
Dermatology
728
1861480857
Internal Medicine
709
1073546479
Dermatology
344
1841376704
Hematology/Oncology
246
1396734505
Orthopedic Surgery
244
1225095763
Gastroenterology
234
1669482576
Internal Medicine
219
1922069475
Urology
172
1235244716
Family Practice
172
1396823167
Internal Medicine
148
*These referrals represent the top 10 that Dr. Gajjar has made to other doctors

Publications

Analysis of histologic and clinical changes associated with Polaris WR treatment of facial wrinkles. - Aesthetic surgery journal / the American Society for Aesthetic Plastic surgery
The Polaris WR is a device that combines laser energy with radiofrequency (RF) treatment to provide more focused RF energy on the skin to reduce wrinkles and/or tighten skin. Clinical results have varied from highly visible to no obvious reduction in wrinkles.This prospective study investigated whether there was any corollary between clinical results, standardized VISIA (Canfield Imaging Systems, Fairfield, NJ) and digital photographs, and skin biopsy analysis after the treatment of facial wrinkles with the Polaris WR device.Fifteen patients received four full-face treatments. Biopsy of the treated skin was performed before and 1 and 3 months after their last treatment. A VISIA computer analysis of facial wrinkle density and depth was performed before any treatment and then 3 months after the last treatment. Digital photographs were reviewed by four surgeons to evaluate wrinkle reduction at 3 and 6 months after the four treatments.Physicians' ratings of these digital images revealed that 58% of the patients were improved at 3 months after treatment, and 42% were still improved at 6 months. The patient questionnaire responses revealed that 75% of patients felt that they looked better at 3 months, and 67% felt that they remained improved 6 months after their last treatment. VISIA photographic analysis demonstrated that 67% of the patients had fewer and/or shallower wrinkles at their 3-month visit. The average degree of improvement with VISIA analysis was 30%. Biopsy specimens in the group of patients that were defined as improved by VISIA assessment showed a greater dermal thickness and interfibrillar spacing P < .024). Two patients received superficial second-degree burns that did not require corrective treatment.Improvement in skin wrinkling after Polaris WR therapy was confirmed in patients at 3 months after treatment by physician assessment, VISIA analysis, and patient assessment, with a lower rate of improvement at 6 months after treatment. VISIA analysis tended to confirm patient assessments. Physician assessments of improvement tended to be lower.
Infectious enteritis after intestinal transplantation: incidence, timing, and outcome. - Transplantation
The study reviews the incidence, timing, and outcome of infectious enteritis (IE) after intestinal transplantation (ITx).A retrospective review of all patients who underwent ITx at a single institution between 1991 and 2003 was undertaken using database and medical records. Standard statistical analyses were performed.Of 33 ITx recipients, 13 (39%) developed 20 culture- or biopsy-proven episodes of IE. Recipient demographics included the following: 10 males, median age 34 (10-585) months, 11 liver + intestine grafts, and two isolated intestine grafts. Infections were diagnosed a median of 76 days (32-1,800 days) after ITx. There were 14 viral (one cytomegalovirus, eight rotavirus, four adenovirus, one Epstein-Barr virus), three bacterial (Clostridium difficile), and three protozoal (one Giardia lamblia, two Cryptosporidium) infections. The bacterial infections tended to present earlier than the viral infections, and the most frequent presenting symptom was diarrhea. Complete resolution was achieved in 17 (94%) incidences with the appropriate antimicrobial or conservative therapy. It was interesting that there were seven rejection episodes documented by biopsy at the approximate time of diagnosis of IE. There were two graft losses: one because of adenoviral enteritis and one because of rejection after rotavirus enteritis. Three-year patient survival is 74% with no deaths directly attributable to IE.IE can occur in 39% of recipients after ITx. Viral agents are the cause in two thirds of the cases. With supportive care and appropriate treatment, resolution is possible in the majority of cases. Differentiating rejection and infection on histopathology can be difficult and relies on cultures and immunostaining.
Outcomes of acute rejection after interferon therapy in liver transplant recipients. - Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
Interferon alfa has been increasingly used against recurrent hepatitis C (HCV) disease in post-liver transplant (LT) recipients. A serious potential adverse effect is acute rejection. We reviewed our experience using interferon-based therapy (interferon or pegylated interferon with or without ribavirin) for treating recurrent HCV in LT recipients. Forty-four LT recipients were treated with interferon for recurrent HCV. Five of the 44 patients developed acute rejection during interferon-based therapy. These 5 patients started treatment of 42.4 +/- 33.89 months (mean +/- SD) after LT. Mean (+/- SD) histological activity index and fibrosis scores before initiating antiviral therapy were 8.8 (+/- 1.92) and 2.6 (+/- 0.55), respectively. Patients were treated for 3.3 +/- 2.28 months (mean +/- SD) prior to rejection. At the time of rejection, HCV load was not detectable in 4 of the 5 recipients. All 5 patients had tolerated interferon therapy, and none had stopped therapy because of adverse effects. The rejection was successfully treated in 3 patients. In 2 of those 3 patients, cirrhosis eventually developed. In the 2 patients who did not respond to rejection treatment, immediate graft failure occurred, leading to re-LT in 1 patient and death from sepsis in the other. In conclusion, the results indicate that further studies are needed to assess the safety of interferon in LT recipients. Interferon-based therapy may lead to acute rejection and subsequent graft loss and should therefore be used with caution. Treated recipients may also develop progressive cirrhosis despite achieving a sustained virological response.
Is MAGE-1 expression in metastatic malignant melanomas really helpful? - The American journal of surgical pathology
Melanoma antigen-encoding gene (MAGE-1) has been introduced as a sensitive immunohistochemical marker to aid in the diagnosis of malignant melanomas, in particular, those that are HMB-45 negative. Our goal was to determine the consistency of positive staining in melanomas on the basis of the usefulness of MAGE-1 in comparison with tyrosinase and MART-1. We studied 56 malignant melanomas using immunohistochemical markers to MAGE-1, tyrosinase, MART-1, HMB-45, and S-100. Six of 17 HMB-45-negative cases were strongly positive for MAGE-1 (35%), while 9 of 39 HMB-45-positive cases were positive for MAGE-1 (23%), overall, 27% positivity (n = 56). Tyrosinase and MART-1 were both strongly positive in 42 of 56 cases (75%). Fifty-two of 56 cases were strongly positive for S-100 (93%). We found MAGE-1 to be less sensitive than described in other studies, and overall, not very helpful, especially as a predictor of aggressive behavior. Although MAGE-1 expression has been considered as a target for immunomodulation therapy, our findings do not indicate consistent expression of this epitope in a majority of melanomas. S-100 protein, tyrosinase, and MART-1 immunomarkers were more frequently positive in our melanoma cases and appear to constitute a useful panel of markers to aid in the diagnosis of metastatic malignant melanomas, especially in patients with an unknown primary.
Fine-needle aspiration biopsy as an adjunct to the diagnosis of a rare adnexal tumor of hair follicle origin: trichoblastoma. - Diagnostic cytopathology
Fine-needle aspiration biopsy (FNAB) is a technique used increasingly for the investigation of primary and metastatic cutaneous tumors. Trichoblastoma is a rare benign skin appendage tumor of hair germ origin. We report the diagnosis by FNAB of a rare giant subcutaneous tumor, trichoblastoma, from an 81-yr-old woman with a subcutaneous mass in the interscapular area of her back. The cytologic characteristics of the tumor are discussed in detail in this report. The findings have been compared with the histologic features of the tumor after surgical excision. We have characterized several distinctive cytologic features that may aid in the diagnosis of this rare neoplasm. While most reported cases have been diagnosed from surgical excisional biopsy specimens, FNAB may also be a valuable tool for the accurate diagnosis of trichoblastoma in the proper clinical context.Copyright 2003 Wiley-Liss, Inc.
FK506 vs. cyclosporin. Pathologic findings in 1067 endomyocardial biopsies. - Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology
Whether FK506 or cyclosporin is better for chronic immunosuppression in heart transplant patients has been debated. We examined endomyocardial biopsies from patients treated with these two drugs to determine if there was a difference in frequency of histologic cellular rejection episodes and Quilty lesions. The Quilty lesion (AKA cyclosporin effect) may be an atypical form of rejection, and is thought to be related to the use of cyclosporin immunosuppression.We reviewed 1067 endomyocardial biopsies from 65 patients who were assigned FK506 or cyclosporin after heart transplantation.The number of episodes of rejection (162 FK506 vs. 145 cyclosporin) was the same. However, when compared to cyclosporin treatment, FK506 was associated with significantly more Quilty A lesions and fewer Quilty B lesions.FK506 appears to prevent some Quilty A lesions from progressing to Quilty B lesions. Since Quilty B lesion is associated with myocyte injury and Quilty A is not, this effect of FK506 could be associated with improved long-term graft function.Copyright 2003 Elsevier Inc.

Map & Directions

350 Hawthorne Ave Oakland, CA 94609
View Directions In Google Maps

Nearby Doctors

350 Hawthorne Ave
Oakland, CA 94609
510 554-4000
6117 Martin Luther King Jr Way
Oakland, CA 94609
510 554-4896
3875 Telegraph Ave
Oakland, CA 94609
510 472-2244
747 52Nd St
Oakland, CA 94609
510 283-3316
747 52Nd St
Oakland, CA 94609
510 283-3387
747 52Nd St
Oakland, CA 94609
510 283-3885
411 30Th St Ste 508
Oakland, CA 94609
925 744-4950
747 52Nd St
Oakland, CA 94609
510 283-3885
350 Hawthorne Ave
Oakland, CA 94609
510 696-6883
747 52Nd St
Oakland, CA 94609
510 283-3000